News
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
New Research in a New England Journal of Medicine Publication Finds Patients of Value-Based Care Organizations Have More Frequent and Consistent Primary Care Visits
A new study published in The New England Journal of Medicine Catalyst, conducted by the Humana Healthcare Research team and Massachusetts General Hospital Attending Physician Dr. Suhas Gondi, who
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application
Humana Announces New Agreements to Expand Specialized Care Programs for Patients Living with Musculoskeletal Conditions
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced new strategic, individual value-based care partnerships with Vori Health and HOPCo, in addition to the company’s
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
-
The 2025 Wells Fargo Healthcare Conference on
Humana Earns 2025 Great Place to Work Certification™ and PEOPLE Companies That Care® Recognition
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has been named a Certified™ Great Place To Work® for the fourth consecutive year and has earned a place on
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
-
Revenue grew 15% year-over-year to
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process
Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians
Sartorius Stedim Biotech SA: Information on Document Availability
Half-year results 2025 of Sartorius Stedim Biotech
Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE: A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes
Humana Simplifies Access to Coverage and Care Information
Humana Inc. [NYSE: HUM] announced today its latest collaboration with healthcare software company Epic, becoming the first health insurer to integrate health plan information directly into the
Agilent Announces CFO Transition
Agilent Technologies Inc. (NYSE: A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the
Humana Foundation Responds to Central Texas Flood Tragedy with $500,000 in Recovery Support
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today a $500,000 donation to aid recovery efforts in Central Texas following the tragic flooding that struck over the
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL